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E-mail address: jbernhagen@ukaachen.de (J. BernhCSN5/JAB1 is a critical subunit of the COP9 signalosome (CSN) and is overexpressed in many human
cancers, but little is known about the role of CSN5 in colorectal cancer (CRC). To explore the func-
tional role of CSN5 in colorectal tumorigenesis, we applied siRNA technology to silence CSN5 in HeLa,
SW480, HCT116, HT29, and CaCo2 cells. CSN5 knock-down led to reduced b-catenin and phospho-b-
catenin levels and this was paralleled by reduced CRC cell proliferation and reduced apoptosis rates,
whereas the short-term b-catenin protein stability was enhanced by CSN5 knock-down in SW480
cells. Together, these data implicate the CSN in the pathogenesis of CRC via regulation of the Wnt/
b-catenin pathway.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
C-Jun activation domain binding protein-1 (JAB1) is the ﬁfth
subunit of the constitutive photomorphogenesis-9 (COP9) signalo-
some (CSN). The CSN is an essential multifunctional protein com-
plex that was ﬁrst discovered in plants and characterized as a
negative regulator of photomorphogenesis, but that is now known
to be expressed in all eukaryotic cells and to be highly conserved
from yeast to mammals [1,2]. The CSN complex consists of 8 sub-
units named CSN1 to CSN8 according to their size [3,4]. The active
composition of the CSN is under debate; both a holocomplex and a
subcomplex called ‘‘mini-CSN’’ have been described [4–6]. The CSN
is a central regulator of critical biological responses in several spe-
cies such as embryonic development and oocyte maturation, T cell
development, signal transduction in inﬂammation and cancer, cell
cycle progression, and DNA damage control [4,7–10]. These diverse
biological responses have been attributed to three major biochem-
ical activities of the CSN. First, the CSN regulates the activity of cul-
lin-RING ubiquitin ligases (CRLs) by removing the ubiquitin-like
modiﬁer NEDD8 from cullins. DeNEDDylation stabilizes CRLs bychemical Societies. Published by E
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genesis; CSN, COP9 signalo-
tin ligase; CSN5, ﬁfth subunit
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agen).limiting the autocatalytic destruction of F box substrate adaptor
proteins. Accordingly, the CSN is a pivotal regulator of ubiquitin
(Ub)/26 S proteasome (UPS)-dependent protein degradation pro-
cesses of a variety of cell cycle and survival-regulatory proteins
[11–13]. Secondly, the CSN serves as a docking platform for protein
kinases and thus plays a critical role in signal transduction cas-
cades [4,7,8]; it also recruits deubiquitylases (DUBs) such as
Usp15, which contribute to reverse spurious CRL auto-ubiquityla-
tion events and lead to the deubiquitylation of the CRL substrate
IjB-a, resulting in an attenuation of the NFjB signaling pathway
[14]. Thirdly and most recently, it has been suggested that the
CSN also regulates transcriptional activity by direct interaction
with chromatin [15]. It is likely that the main activities of the
CSN are inter-connected with each other. In addition, the stability
and activity of the CSN may be modulated by CSN-interacting ki-
nases such as IjB kinase (IKK) [16]. Moreover, CSN5 which has
been reported to additionally exist in a free, non-CSN-associated
form, apparently has functions that are independent of the CSN
particle and serves as a transcriptional coactivator and assists in
the nuclear export of cell cycle proteins [17–19].
An aberrant expression of the CSN, in particular its subunit
CSN5, has been observed in a variety of human cancers [8]. CSN5
was found to be overexpressed in breast cancer, hepatocellular car-
cinoma, neuroblastoma, epithelial ovarian tumors, lung adenocar-
cinoma, pancreatic cancer, and oral squamous cell carcinoma. This
has led to the suggestion that the CSN, especially CSN5, generally
promotes tumorigenesis [8,20–26]. The molecular basis for an
association between the CSN and cancer is not fully understood,lsevier B.V. All rights reserved.
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malian CSN is involved in cell cycle regulation, signal transduction,
checkpoint control and apoptosis. For example, CSN5 interacts
with the cyclin-dependent kinase (CDK) inhibitor p27Kip1 to pro-
mote its UPS-mediated degradation and also regulates the ubiqui-
tin E3 ligase SCFSkp2 which controls p27 degradation [18,27]. CSN-
associated kinases phosphorylate the tumor suppressor protein
p53 and the CSN associates with the major p53-degrading Ub li-
gase Mdm2, together resulting in p53 destabilization and degrada-
tion [28]. Mdm2 itself is stabilized by CSN5 through reduction of
Mdm2 self-ubiquitylation [29]. Despite this evidence, a recent
study has indicated that the role of the CSN in cancerogenesis is
likely to be more complex [30].
Colorectal cancer (CRC) is one of the most frequent cancers
worldwide and a leading cause of cancer-related death in the
Western world, which beyond genetic predisposition is thought
to be associated with dietary habits, such as high fat and low ﬁ-
ber food intake [31,32]. In most individuals, adenomatous polyps
develop before transformation into an adenocarcinoma occurs.
The Wnt/adenomatous polyposis coli (APC)/b-catenin pathway is
one of the major signaling pathways involved in colorectal cancer
formation [33]. In fact, mutations in the APC tumor suppressor
gene initiate the process of colorectal carcinogenesis [34]. In nor-
mal colon epithelial cells, APC attenuates Wnt/Frizzled signaling
by promoting b-catenin degradation through the UPS pathway
[35]. This is achieved by APC’s central role in the so-called
destruction complex (DC) which consists of axin, glycogen syn-
thase kinase-3b (GSK-3b), and casein kinase 1 (CK1). DC-associ-
ated GSK-3b phosphorylates b-catenin, in turn targeting it for
ubiquitination by the SCFb-TrCP1-CRL E3 ligase and subsequent
degradation [36–38]. In cells harboring mutated APC and/or un-
der conditions of constitutive activation of the Wnt/Frizzled path-
way, b-catenin accumulates and, following its translocation into
the nucleus, it co-activates the transcription factor TCF-LEF,
resulting in b-catenin/TCF-LEF-dependent transcriptional activa-
tion of critical cell cycle regulatory genes, such as c-Myc and cy-
clin D1 [33]. In CRC, APC or b-catenin itself are frequently
mutated, preventing regulated degradation of b-catenin.
Here, we have studied the potential functional role of the CSN in
regulating the tumorigenic behavior of CRC cells by silencing CSN5
in different human model and CRC cell lines in vitro. Both phos-
pho-b-catenin and total b-catenin levels were reduced in SW480
and HeLa cells after CSN5 knock-down when compared with
scrambled RNA-treatment, while CSN5 knock-down also ablated
short-term b-catenin degradation in SW480 cells. The potential
functional relevance for CSN5 was further analyzed by studying
CSN5-dependent CRC cell proliferation and apoptosis.2. Materials and methods
2.1. Cell culture and knock-down of CSN5 or of b-catenin/CTNNB1
Cell culture reagents including media, supplements and antibi-
otics were from Gibco/Invitrogen. Cell culture experiments were
generally performed at 37 C and in a humidiﬁed incubator with
5% CO2. HeLa and CaCo2 cells were cultured in Dulbecco’s Modiﬁed
Eagle Medium (DMEM) supplemented with Glutamax containing
4.5 g/l D-glucose and sodium pyruvate, containing 10% fetal calf
serum (FCS) and 1% penicillin/streptomycin (P/S). SW480 cells
were cultured in RPMI 1640 medium containing 5% FCS and 1%
P/S. HCT116 cells were cultured in McCoy’s 5A medium with 10%
FCS and 1% P/S. HT29 cells were cultured in DMEM medium with
5% FCS and 1% P/S.
For knock-down experiments, cells were seeded in a 12-well-
plate using 80000 cells/well the day before (si)RNA-transfection.For CSN5 knock-down cells were transfected with 100 pmoles of
CSN5-speciﬁc CSN5siRNA1 (GCUCAGAGUAUCGAUGAAATT) [39]
or CSN5siRNA2 (AGAAGUACUUUACCUGAAAUU) [40]. For
CTNNB1/b-catenin knockdown, cells were transfected with 100
pmoles of b-catenin-siRNA1 (AGCUGAUAUUGAUGGACAGTT) or b-
catenin-siRNA2 (CAGUUGUGGUUAAGCUCUUTT) [41]. For control
transfections, a scrambled RNA (CAGAAGCUAGUUACGAGAUTT)
was applied. Transfections (Oligofectamine transfection reagent
from Invitrogen) were performed for 72 h or 96 h.
2.2. SDS–PAGE and Western blot
Cells were directly lysed in LDS sample buffer (Invitrogen) sup-
plemented with DTT. SDS–PAGE was performed in 12% acrylamide
gels. Proteins were blotted onto a nitrocellulose membrane and
membranes were blocked with 1% BSA (Albumin fraction V, Roth).
The following antibodies were used: anti-CSN5/JAB1 (rabbit poly-
clonal IgG; FL-334; Santa Cruz), anti-b-catenin (puriﬁed mouse
IgG1; BD Transduction Laboratories), anti-phospho-b-catenin
((Thr41/Ser45); rabbit polyclonal; Cell Signaling), anti-CSN1 and
anti-CSN8 (rabbit polyclonal; Afﬁniti Research), anti-p27 (rabbit
polyclonal IgG; C-19; Santa Cruz), anti-p53 (mouse monoclonal
IgG2a; DO-1; Santa Cruz), anti-MIF (rabbit polyclonal antibody;
Ka565; Bernhagen Lab), and anti-actin (mouse monoclonal, clone
C4, MP Biomedicals). Secondary antibodies (anti-rabbit or anti-
mouse) were purchased from Pierce/Thermo Fisher Scientiﬁc. Blots
were detected with the LAS-3000 image analyzer and bands quan-
titated densitometrically using AIDA software. Relative protein lev-
els were obtained using actin bands for normalization.
2.3. Pulse chase assay
SW480 cells were seeded in a 24-well-plate using 80000 cells/
well. The next day, cells were si(RNA)-transfected as described in
2.1 to achieve CSN5 knock-down. 96 h after transfection, cyclohex-
imide (CHX, Sigma) was added to a ﬁnal concentration of 10 lg/ml
to block de novo protein synthesis. Samples were taken before add-
ing cycloheximide (time point 0 h) and 1, 2, 4, 6 and 8 h after CHX
treatment. Cell lysates were analyzed by SDS–PAGE and Western
blot.
2.4. Proliferation/BrdU assay and overexpression of CSN5
Following transfection with siRNA or scrambled control RNA
(see above) for 72 h, cells were seeded in a 96-well plate at 8000
cells/well. The proliferation assay was performed with the Cell Pro-
liferation ELISA, BrdU (colorimetric) Kit from Roche Diagnostics
according to the manufacturer’s instructions. BrdU labeling was
performed for a period of 4 h the day after seeding the cells to a
96-well plate.
For overexpression of CSN5, SW480 cells were seeded into a 12-
well plate and ﬁrst siRNA-transfected the next day. Forty-eight
hours later, a CSN5-overexpression construct (pcDNA5-C-TAP-
CSN5) or a respective control vector was transfected using PolyFect
Transfection Reagent (Qiagen). The next day, cells were seeded to a
96-well plate and BrdU assay performed as described above. To
determine b-catenin knock-down and CSN5-overexpression efﬁ-
ciencies, cells were lysed and analyzed by SDS–PAGE/Western blot
in parallel.
2.5. Apoptosis/caspase 3 assay
HCT116 cells were seeded in a 24-well-plate using 80000 cells/
well. The next day, cells were (si)RNA-transfected as already
described to achieve CSN5 knock-down. Forty-eight hours after
transfection, 500 lM etoposide or an equivalent volume of DMSO
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sis was measured with a Caspase-3 colorimetric assay from R&D
Systems according to the manufacturer’s instructions. Cells were
lysed in 120 ll lysis buffer. For each sample, duplicate aliquots of
50 ll lysate were added to a 96-well plate. CSN5 knock-down
efﬁciency was tested by SDS–PAGE and Western blotting in
parallel.
3. Results
3.1. CSN5 knock-down reduces b-catenin levels in HeLa cells
We wished to assess a potential functional role of CSN5 and the
CSN in CRC using model and colorectal cancer cell lines. Because
CSN5 is essential for CSN’s major functions due to its inherent
deNEDDylase activity, we chose to knock-down CSN5 by siRNA-
mediated gene silencing or ectopically overexpress CSN5 and fo-
cused our analysis on the Wnt/b-catenin pathway.
We ﬁrst studied the CSN dependency of b-catenin in HeLa
cells. HeLa is a typical tumor cell line, but harbors no known
mutations in the Wnt/b-catenin signaling pathway, such that b-
catenin would be predicted to be normally degraded by the
UPS. CSN5-siRNA treatment of HeLa cells for 72–96 h led to a
reduction in CSN5 levels by 55% using CSN5-siRNA1 (Fig. 1).
CSN5 knock-down was conﬁrmed using an alternative siRNA se-
quence (CSN5-siRNA2) with which we achieved a reduction in
CSN5 protein levels by 50% (Supplemental Fig. 1). Reduction
of CSN5 but not treatment of cells with scrambled RNA was asso-
ciated with signiﬁcantly lowered phospho-(Thr41/Ser45)-b-cate-
nin protein levels by 30% as revealed by Western blot analysis
from lysates of the transfected HeLa cells. Total b-catenin levels
were also found to be reduced following CSN5 knock-down (10–
20%), but this effect did not reach statistical signiﬁcance and
was thus considered a trend only. Together, this indicated that0
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Fig. 1. Knock-down of CSN5 reduces b-catenin and phospho-b-catenin levels in
HeLa cells. CSN5 levels were reduced by siRNA silencing (72 h transfection) and
protein levels studied by SDS–PAGE/Western blot. (a) Representative Western blot
developed for CSN5, b-catenin, phospho-b-catenin and actin as loading control; (b)
quantiﬁcation of protein levels according to (a). Shown are means ± SEM of four
independent experiments done in triplicate each. ⁄p < 0.05, ⁄⁄p < 0.005.CSN5 functionally affects b-catenin levels in HeLa cells. As phos-
phorylation of b-catenin at Thr41 and Ser45 is a prerequisite for
its UPS-mediated degradation, these results also suggested that
CSN5 and/or the CSN is involved in b-catenin degradation and
regulation of the Wnt/b-catenin pathway.
3.2. CSN5 knock-down reduces overall b-catenin levels in CRC cells but
also ablates b-catenin degradation
SW480 cells represent a RAS-mutated human colorectal adeno-
carcinoma cell line in which also theWnt signaling pathway is con-
stitutively activated due to a mutation in the APC protein, reducing
ubiquitination and degradation of b-catenin [42]. We asked
whether siRNA-mediated knock-down of CSN5would further affect
b-catenin levels in these cells. Transfection of SW480 cells with
CSN5-speciﬁc siRNA led to a 50% reduction in CSN5 protein levels
compared to scrambled control RNA-treated cells (Fig. 2) using
CSN5-siRNA1 and to a 80% reduction using CSN5-siRNA2 (Supple-
mental Fig. 1). Of note, CSN5 knock-down also led to a reduction in
the protein levels of CSN1 and CSN8 indicating that the entire CSN
complex was affected (Fig. 2a and b; Supplemental Fig. 2). Analysis
of b-catenin revealed that the functional effect of CSN5 reduction
that we had observed in HeLa cells could also be seen in the
SW480 CRC cells. b-catenin protein levels were markedly and sig-
niﬁcantly lowered by 20-50% (using CSN5-siRNA2- and CSN5-siR-
NA1-mediated knock-down, respectively) but not following
scrambled RNA treatment (Fig. 2 and Supplemental Fig. 2). Phos-
pho-(Thr41/Ser45)-b-catenin levels were also lowered (by some
20% when applying CSN5-siRNA1-mediated knock-down), but
this effect only represented a trend and was not statistically signif-
icant. Interestingly, in SW480 cancer cells no correlation was ob-
served between the levels of CSN5 and the CDK inhibitor protein
p27Kip1, although it has been demonstrated that CSN5 contributes
to p27Kip1 degradation in various cell types. In contrast, p53 protein
levels were moderately yet signiﬁcantly reduced in the CNS5-siR-
NA1 knock-down cells. SW480 cells show elevated p53 levels,
but the p53 protein is at least partially inactivated due to two
mutations. The functional relevance of the observed effect of the
CSN5 knock-down on p53 is thus unclear. Reduction of CSN5 also
did not lead to alterations in levels of the CSN5-interacting protein
MIF. Together, these data indicated that in CRC cells, reduction of
CSN5 protein levels lead to an overall reduction in b-catenin levels
over the 96-hour observation time interval of the transient
transfection.
CSN5 has been reported to promote SCFb-TrCP1-CRL E3 ligase-
mediated degradation of b-catenin in thymocytes [9]. We thus
began to analyze the mechanism underlying the observed re-
duced b-catenin levels in the CSN5-siRNA knock-down SW480
cells. To analyze if CSN5 is involved in b-catenin degradation,
we performed pulse chase studies using CHX. CHX inhibits de
novo protein synthesis, such that observed changes in b-catenin
levels will be due to effects on degradation. As expected, b-cate-
nin protein levels decreased constantly following 0–8 h CHX
treatment of scrRNA-transfected cells (Fig. 2c). In contrast, when
CSN5 levels were reduced by knock-down (CSN5 knock-down
rate: 72%), essentially no reduction in b-catenin levels was ob-
served, but b-catenin levels were elevated compared to the con-
trol-transfected cells. Of note, this difference was statistically
signiﬁcant 6 h after adding CHX to the cells. Although this result
could indicate that in SW480 cells CSN5 would promote the deg-
radation of b-catenin through the APC/SCFb-TrCP1/UPS pathway, it
is unclear at this point whether this is the case, because the activ-
ity of the APC-containing destruction complex is markedly im-
paired in these cells. Thus, CSN5 may also affect an alternative
degradation pathway of b-catenin or affect b-catenin levels
through other processes (see Section 4).
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Fig. 2. Knock-down of CSN5 reduces CSN1 and CSN8 levels as well as the levels of various tumor-relevant proteins in SW480 cells, (a and b) After CSN5 knock-down
(transfection time 96 h) whole cell lysates were analyzed via SDS–PAGE/Western blot for differences in protein levels, (a) A representative blot developed for CSN5, CSN1,
CSN8, b-catenin, phospho-b-catenin, p27, p53, MIF, and actin as loading control, (b) Quantiﬁcation of protein levels according to (a). Shown are means ± SEM of 5–6
independent experiments done in triplicate each. C, CSN5-speciﬁc siRNA knock-down; s, transfection with scrRNA. ⁄p < 0.05, ⁄⁄p < 0.005. (c) SW480 cells were transfected with
CSN5-siRNA. 96 h after transfection, cells were treated with cycloheximide (CHX) and lysed after 0, 1, 2, 4, 6, or 8 h. Cell lysates were analyzed by SDS–PAGE/Western blot for
b-catenin and actin levels. Shown are means ± SD of four independent experiments done in duplicate each.
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We have demonstrated that CSN5 and the CSN have a functional
inﬂuence on b-catenin levels in HeLa and SW480 CRC cells. As con-
stitutive activation of the Wnt/b-catenin pathway promotes prolif-
eration and survival of CRC cells, we next tested whether CSN5regulates cell proliferation in colorectal cancer cell lines. In addition
to SW480, HT29, HCT116, and CaCo2 cells were examined and
subjected to transfections with CSN5-speciﬁc versus scrambled
(si)RNA. Proliferation rates of these cells as a function of CSN5 levels
were subsequently measured by the BrdU incorporation assay
(Fig. 3a). CSN5 knock-down led to considerably reduced
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A.K. Schütz et al. / FEBS Letters 586 (2012) 1645–1651 1649proliferation rates in all four CRC cell lines. This indicated that the
effect of CSN5/CSN on b-catenin correlated with a promoting effect
on the proliferation of adenocarcinoma cells of the colon.
To probe for a potential functional link between CSN5/b-catenin
and cell proliferation, we performed proliferation studies in the
context of a CTNNB1/b-catenin knock-down and simultaneous
overexpression of CSN5 in SW480 cells (Fig. 3b). Knockdown of
b-catenin protein by 80% led to a signiﬁcantly reduced proliferation
rate (50%) compared to scrRNA-transfected cells. Of note, co-
transfection with a CSN5-overexpression construct (overexpression
rate: 20%) partly rescued the reduced proliferative activity in the(si)RNAscr
0.0
0.1
0.2
0.3
0.4
0.5
Br
dU
in
co
rp
or
at
io
n
[O
D
 4
50
 n
m
]
scr β-cateninβ-catenin
p = 0.05
CSN5 
overexpression
control
(b)
scr
Br
dU
in
co
rp
or
at
io
n
[O
D
 4
50
 n
m
] *
CSN5 CSN5CSN5 scr
SW480 HT29 CaCo2
0.0
0.1
0.2
0.3
0.4
(a)
0.5
HCT116
**
(si)RNA scr scrCSN5
Fig. 3. CSN5 promotes the proliferation rate of CRC cells in a b-catenin-dependent
manner as evidenced by CSN5 knock-down and overexpression. (a) CSN5 knock-
down leads to a reduced proliferation rate of CRC cells. Cells were transfected with a
CSN5-siRNA or scrambled control RNA (scr) for 72 h and then seeded to a 96-well
plate. The next day, BrdU uptake was measured for 4 h to determine the
proliferation rate of the CRC cells. Data represent means ± SEM of four independent
experiments performed in duplicate each with triplicate BrdU measurements each
for SW480 cells, two independent experiments performed in duplicate each with
triplicate BrdU measurements each for HCT116 cells (⁄p < 0.05; ⁄⁄p < 0.005, respec-
tively) and one experiment measured in triplicate for HT29 and CaCo2 cells, (b) b-
catenin-knock-down mediated reduction in CRC cell proliferation is rescued by
CSN5 overexpression. SW480 cells were transfected with two different b-catenin-
siRNAs or control RNA (scr). 48 h later, cells were additionally transfected with a
plasmid for CSN5 over-expression or with control vector and seeded in a 96-well
plate after another 24 h. The next day, BrdU uptake was followed for 4 h.
Means ± SD of two experiments (pooled from the two different b-catenin-siRNAs)
performed in duplicate each with triplicate BrdU measurements each are shown.
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Fig. 4. CSN5 knock-down reduces etoposide-stimulated apoptosis in HCT116 CRC
cells. Cells were (si)RNA transfected for 72 h. For the last 24 h, cells were exposed to
etoposide to induce apoptosis or cells were treated with the same amount of DMSO
as control. Caspase 3 activity was measured with a colorimetric assay. The higher
the measured absorption the higher is the caspase 3 activity and thus the apoptosis
rate. Data represent means ± SD of three independent experiments measured in
duplicate each. ⁄⁄p < 0.005.b-catenin-knock-down cells. These data underline the pro-prolifer-
ative effect of CSN5 in CRC cells and suggest a link to its effect on b-
catenin levels.
3.4. Caspase 3 activity is reduced after CSN5 knock-down in CRC cells
After having observed the pro-proliferative effect of CSN5 in dif-
ferent human CRC cell lines, we speculated that CSN5 may have a
broader role in CRC cell behavior. Therefore, we next studied a po-
tential effect of CSN5 on apoptotic cell death in the CRC cell line
HCT116. HCT116 cells, which have a wildtype p53 gene product,
were subjected to transfection with CSN5-speciﬁc or scrambled
(si)RNA and were treated with etoposide to induce apoptosis. To
evaluate apoptosis, the activity of caspase 3, an effector caspase
in the apoptotic cascade, was measured (Fig. 4). Surprisingly,
CSN5 knock-down caused a signiﬁcant reduction in caspase 3 activ-
ity after etoposide treatment compared to HCT116 cells transfec-
ted with scrambled RNA and treated with etoposide. Thus, it
appears that in CRC cells CSN5 can both promote cell proliferation
but also enhance apoptosis.
Together, these results underscore the importance of CSN5 and
presumably the CSN complex in CRC cell fate and CRC
pathogenesis.
4. Discussion
The COP9 signalosome subunit CSN5 has been shown to be
overexpressed in several tumor entities such as breast cancer,
hepatocellular carcinoma, lung adenocarcinoma, or pancreatic can-
cer [22,23,43–45], and numerous in vitro and in vivo studies have
indicated that the CSN promotes tumorigenic cellular properties
and functionally contributes to tumor development [21,27,46,47].
In the current study, we were interested in the possible role of
CSN5 and the CSN in CRC development. To begin to address this
question, we focused on a potential mechanistic contribution of
CSN5 to Wnt/b-catenin signaling. As we observed in SW480 CRC
cells that the reduction of CSN5 also led to signiﬁcantly reduced
CSN1 and CSN8 levels, we conclude that CSN5 also is critical for
the stability of the CSN complex in these cells.
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active pathway is the Wnt pathway with b-catenin as its key com-
ponent. Huang et al. [30] have studied a link between b-catenin
degradation and the CSN and have suggested that the CSN assists
in forming a b-catenin-degrading super-complex through deNED-
Dylation and simultaneous stabilization of APC by CSN-associated
USP15. This conclusion was based on experiments in which CSN1
was downregulated in HeLa cells by a siRNA approach. This led
to retarded b-catenin degradation, indicating that the CSN may
promote b-catenin degradation in these cells. We observed a
similar effect in SW480 CRC cells when we silenced CSN5, the
enzymatically active subunit of the CSN, in combination with
short-term CHX treatment, together indicating a functional role
of the CSN complex in b-catenin degradation processes also in
CRC cells. However, when we studied the effect of CSN5 reduction
on overall – ‘‘long-term’’ – b-catenin levels in HeLa and SW480
cells, we observed that CSN5 knock-down led to a clear-cut reduc-
tion in b-catenin levels as well as in the levels of its phosphorylated
form. Thus, the short-term pro-degradative effects of CSN5 on the
b-catenin protein appear to be overcompensated by CSN5-medi-
ated effects which result in a net elevation of b-catenin levels.
The mechanistic basis for this effect is intriguing but currently fully
unclear and will have to be the subject of future studies, with
counter-regulatory effects on alternative b-catenin degradation
pathways and regulation of b-catenin expression by CSN5 being
potential responsible processes. Along these lines, it should be
emphasized that there are certain mutations in the Wnt signaling
pathway itself harbored by the SW480 cells used in this study.
SW480 cells have a truncated APC (only the N-terminus is left),
so that the destruction complex as part of the canonical Wnt path-
way is strongly impaired in its capacity to initiate b-catenin degra-
dation. This could mean that CSN5 might not primarily inﬂuence
canonical b-catenin degradation in these cells, but might also have
an effect on an alternative b-catenin degradation pathway. Xiao
et al. described an APC-independent regulation of b-catenin degra-
dation involving retinoid X receptors (RXRs) [48]. It may be specu-
lated that the CSN has an impact on RXR-mediated b-catenin
degradation processes. In summary, it may be concluded from both
types of studies that the CSN promotes rapid b-catenin degradation
on the one hand, but could also be essential for long-term b-catenin
stability.
CSN5 is known to promote p27 degradation by accelerating its
transport from the nucleus to the cytoplasm [6,18]. Additionally in
some cancers, such as hepatocellular carcinoma [49] or pancreatic
adenocarcinoma [50], CSN5-overexpression correlates inversely
with p27 levels. However in CRC cells, we did not obtain hints sup-
porting this previously described link between CSN5 and p27, as
we did not observe any difference in p27 levels between CSN5-siR-
NA-treated cells and control cells. However, the experimental ap-
proach in the studies by Kouvaraki et al. and Berg et al. was
different, as it relied on CSN5-overexpression in pancreatic carci-
noma or hepatoma cells, which resulted in reduced p27 levels.
Tomoda et al. reduced CSN5 levels by 20–30% in myelogenous leu-
kemia K562 cells and observed an accumulation of p27 [21]. By
comparison, we reduced CSN5 protein levels by up to 60-70% in
SW480 cells, but could not see any increase in p27 protein. Inter-
estingly, the levels of p27 were also consistently reduced in
CSN5del/del DN cells, a knock-out thymocyte variant in which
CSN5 was substantially reduced [9]. One obvious possible reason
for these differing observations could be tissue (cell type)-speciﬁc
differences, but also more detailed kinetic and pulse chase studies
may be warranted to explore this issue further. CSN5 also binds to
p53 and promotes its nuclear export and subsequent Mdm2-med-
iated degradation [19,28,29]. Thus, under physiological conditions
CSN5 contributes to keep p53 levels low. In cancer cells, CSN5-
overexpression would further promote low p53 levels and thuspromote tumorigenesis. Inversely, reduced CSN5 levels should be
associated with elevated p53 levels. We observed reduced p53 lev-
els when CSN5 was silenced in SW480 cells, but this supposed dis-
crepancy may be at least partly explained by the several mutations
that the p53 gene carries in this cell line, and which prevent p53
regulation. Additionally, CSN5 is only one of several regulators of
p53 in cells. Intracellular MIF interacts with CSN5, and MIF antag-
onizes critical CSN5-dependent pathways [51], but our data in
SW480 cells suggest that CSN5 is not essential for MIF stability
in CRC cells. MIF is overexpressed in several tumor entities and is
seen as a tumor promoter. The regulation of MIF levels might play
an essential role also in colorectal tumorigenesis as already sug-
gested by Wilson et al. [52]. Yet, the mechanism(s) responsible
for stabilizing the MIF protein and those promoting MIF degrada-
tion are unknown. Interestingly, recently Schulz et al. identiﬁed
HSP90 chaperone as a key mediator of MIF accumulation in certain
cancer cells [53]. However, it remains to be elucidated if HSP90
also plays a role for MIF stability in SW480 cells.
Denti et al. reduced CSN5 in HEK293T cells and Fukumoto et al.
performed CSN5 knock-down experiments in pancreatic cancer cell
lines. Both groups observed impaired proliferation rates [27,54]. In
accordance with these ﬁndings, we determined impaired prolifer-
ation rates in several CRC cell lines after CSN5 knock-down. The
Wnt signaling pathway and thus b-catenin stabilization is known
to be involved in stem cell proliferation and cancer development
[55]. Our data in HeLa and SW480 cells suggest that CSN5/CSN
leads to an overall elevation of b-catenin levels and the observed
partial rescue of the b-catenin-knock-down-elicited reduction of
CRC proliferation by CSN5 overexpression offers an initial func-
tional link between regulation of b-catenin levels by CSN5 and
CRC cell proliferation. Pro-proliferative effects of tumor-promoting
proteins often, but not necessarily, correlate with anti-apoptotic
activities. For example, oncoproteins such as c-Myc show both
pro-proliferative and pro-apoptotic effects. c-Myc-deﬁcient intesti-
nal cells proliferate slower than wild-type cells [56], but c-Myc also
sensitizes cells to apoptotic triggers by augmenting the death
receptor pathway and priming the mitochondria to release cyto-
chrome c [57,58]. Our experiments support the notion that CSN5
has a pro-apoptotic effect in CRC cells. However, this conclusion
is based on experiments performed in HCT116 CRC cells; thus fu-
ture experiments will need to be extended to other CRC cell lines.
In summary, in the current study we have gathered evidence
that the reduction of CSN5 levels in model and CRC cells lead to
a signiﬁcant reduction of (phospho-)b-catenin levels, indicating
that CSN5 is likely critical for the regulation of b-catenin levels
and the associated Wnt signaling. This is paralleled by a pro-prolif-
erative and pro-apoptotic role of CSN5/JAB1 in CRC cells. Although
our study naturally has a number of limitations that are inherent to
in vitro studies relying on experimentally manipulated cell lines,
they point to an important role of CSN5 and possibly the CSN com-
plex in CRC tumorigenesis.Acknowledgements
We thank H. Lue and B. Lüscher and the members of the Aachen
START consortium on molecular tumor markers for valuable dis-
cussions and B. Lennartz for help with the cell proliferation assays.
This study was supported by the START consortium grant 69605 5/
project P6 of the Medical Faculty of RWTH Aachen University.Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.febslet.
2012.04.037.
A.K. Schütz et al. / FEBS Letters 586 (2012) 1645–1651 1651References
[1] Chamovitz, D.A., Wei, N., Osterlund, M.T., von Arnim, A.G., Staub, J.M., Matsui,
M. and Deng, X.W. (1996) The COP9 complex, a novel multisubunit nuclear
regulator involved in light control of a plant developmental switch. Cell 86,
115–121.
[2] Wei, N. and Deng, X.W. (2003) The COP9 signalosome. Annu. Rev. Cell Dev.
Biol. 19, 261–286.
[3] Kapelari, B., Bech-Otschir, D., Hegerl, R., Schade, R., Dumdey, R. and Dubiel, W.
(2000) Electron microscopy and subunit-subunit interaction studies reveal a
ﬁrst architecture of COP9 signalosome. J. Mol. Biol. 300, 1169–1178.
[4] Wei, N., Serino, G. and Deng, X.W. (2008) The COP9 signalosome: more than a
protease. Trends Biochem. Sci. 33, 592–600.
[5] Sharon, M., Mao, H., Boeri Erba, E., Stephens, E., Zheng, N. and Robinson, C.V.
(2009) Symmetrical modularity of the COP9 signalosome complex suggests its
multifunctionality. Structure 17, 31–40.
[6] Tomoda, K. et al. (2002) The cytoplasmic shuttling and subsequent
degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome
complex. J. Biol. Chem. 277, 2302–2310.
[7] Bech-Otschir, D., Seeger, M. and Dubiel, W. (2002) The COP9 signalosome: at
the interface between signal transduction and ubiquitin-dependent
proteolysis. J. Cell Sci. 115, 467–473.
[8] Kato, J.-y. and Yoneda-Kato, N. (2009) Mammalian COP9 signalosome. Genes
Cells 14, 1209–1225.
[9] Panattoni, M. et al. (2008) Targeted inactivation of the COP9 signalosome
impairs multiple stages of T cell development. J. Exp. Med. 205, 465–477.
[10] Tomoda, K., Yoneda-Kato, N., Fukumoto, A., Yamanaka, S. and Kato, J.Y. (2004)
Multiple functions of Jab1 are required for early embryonic development and
growth potential in mice. J. Biol. Chem. 279, 43013–43018.
[11] Chamovitz, D.A. and Segal, D. (2001) JAB1/CSN5 and the COP9 signalosome. A
complex situation. EMBO Rep. 2, 96–101.
[12] Cope, G.A. and Deshaies, RJ. (2003) COP9 signalosome: a multifunctional
regulator of SCF and other cullin-based ubiquitin ligases. Cell 114, 663–671.
[13] Wolf, D.A., Zhou, C. and Wee, S. (2003) The COP9 signalosome: an assembly
and maintenance platform for cullin ubiquitin ligases? Nat. Cell Biol. 5, 1029–
1033.
[14] Schweitzer, K., Bozko, P.M., Dubiel, W. and Naumann, M. (2007) CSN controls
NF-kappaB by deubiquitinylation of IkappaBalpha. EMBO J. 26, 1532–1541.
[15] Chamovitz, D.A. (2009) Revisiting the COP9 signalosome as a transcriptional
regulator. EMBO Rep. 10, 352–358.
[16] Orel, L., Neumeier, H., Hochrainer, K., Binder, B.R. and Schmid, J.A. (2010)
Crosstalk between the NF-kappaB activating IKK-complex and the CSN
signalosome. J. Cell. Mol. Med. 14, 1555–1568.
[17] Claret, F.-X., Hibi, M., Dhut, S., Toda, T. and Karin, M. (1996) A new group of
conserved coactivators that increase the speciﬁcity of AP-1 transcription
factors. Nature 383, 453–457.
[18] Tomoda, K., Kubota, Y. and Kato, J. (1999) Degradation of the cyclin-
dependent- kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398, 160–
165.
[19] Oh, W., Lee, E.W., Sung, Y.H., Yang, M.R., Ghim, J., Lee, H.W. and Song, J. (2006)
Jab1 induces the cytoplasmic localization and degradation of p53 in
coordination with Hdm2. J. Biol. Chem. 281, 17457–17465.
[20] Adler, A.S., Lin, M., Horlings, H., Nuyten, D.S., van de Vijver, MJ. and Chang, H.Y.
(2006) Genetic regulators of large-scale transcriptional signatures in cancer.
Nat. Genet. 38, 421–430.
[21] Tomoda, K., Kato, J.Y., Tatsumi, E., Takahashi, T., Matsuo, Y. and Yoneda-Kato,
N. (2005) The Jab1/COP9 signalosome subcomplex is a downstream mediator
of Bcr-Abl kinase activity and facilitates cell-cycle progression. Blood 105,
775–783.
[22] Kouvaraki, M.A., Rassidakis, G.Z., Tian, L., Kumar, R., Kittas, C. and Claret, F.X.
(2003) Jun activation domain-binding protein 1 expression in breast cancer
inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res. 63,
2977–2981.
[23] Fukumoto, A. et al. (2004) Prognostic signiﬁcance of localized p27Kip1 and
potential role of Jab1/CSN5 in pancreatic cancer. Oncol. Rep. 11, 277–284.
[24] Sui, L., Dong, Y., Ohno, M., Watanabe, Y., Sugimoto, K., Tai, Y. and Tokuda, M.
(2001) Jab1 expression is associated with inverse expression of p27(kip1) and
poor prognosis in epithelial ovarian tumors. Clin. Cancer Res. 7, 4130–4135.
[25] Patil, M.A. et al. (2005) Array-based comparative genomic hybridization
reveals recurrent chromosomal aberrations and Jab1 as a potential target for
8q gain in hepatocellular carcinoma. Carcinogenesis 26, 2050–2057.
[26] Shintani, S., Li, C., Mihara, M., Hino, S., Nakashiro, K. and Hamakawa, H. (2003)
Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1)
and poor prognosis in oral squamous cell carcinomas. Oncology 65, 355–362.
[27] Denti, S., Fernandez-Sanchez, M.E., Rogge, L. and Bianchi, E. (2006) The COP9
signalosome regulates Skp2 levels and proliferation of human cells. J. Biol.
Chem. 281, 32188–32196.
[28] Bech-Otschir, D., Kraft, R., Huang, X., Henklein, P., Kapelari, B., Pollmann, C. and
Dubiel, W. (2001) COP9 signalosome-speciﬁc phosphorylation targets p53 to
degradation by the ubiquitin system. EMBO J. 20, 1630–1639.
[29] Zhang, X.-C., Chen, 1., Su, C.-H., Yang, H.-Y. and Lee, M.-H. (2008) Roles for
CSN5 in control of p53/MDM2 activities. J. Cell. Biochem. 103, 1219–1230.[30] Huang, X., Langelotz, C., Hetfeld-Pechoc, B.K., Schwenk, W. and Dubiel, W.
(2009) The COP9 signalosome mediates beta-catenin degradation by
deneddylation and blocks adenomatous polyposis coli destruction via
USP15. J. Mol. Biol. 391, 691–702.
[31] Walther, A., Johnstone, E., Swanton, C., Midgley, R., Tomlinson, I. and Kerr, D.
(2009) Genetic prognostic and predictive markers in colorectal cancer. Nat.
Rev. Cancer 9, 489–499.
[32] Tanaka, T. (2009) Colorectal carcinogenesis: review of human and
experimental animal studies. J. Carcinog. 8, 5.
[33] Phelps, R.A. et al. (2009) A two-step model for colon adenoma initiation and
progression caused by APC loss. Cell 137, 623–634.
[34] Kinzler, K.W. and Vogelstein, B. (1996) Lessons from hereditary colorectal
cancer. Cell 87, 159–170.
[35] Clevers, H. (2006) Wnt/beta-catenin signaling in development and disease.
Cell 127, 469–480.
[36] Aberle, H., Bauer, A., Stappert, J., Kispert, A. and Kemler, R. (1997) Beta-catenin
is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797–3804.
[37] Polakis, P. (2002) Casein kinase 1: a Wnt’er of disconnect. Curr. Biol. 12, R499–
R501.
[38] Hart, M. et al. (1999) The F-box protein beta-TrCP associates with
phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol.
9, 207–210.
[39] Kim, B.C. et al. (2004) Jab1/CSN5, a component of the COP9 signalosome,
regulates transforming growth factor beta signaling by binding to Smad7 and
promoting its degradation. Mol. Cell Biol. 24, 2251–2262.
[40] Adler, A.S., Littlepage, L.E., Lin, M., Kawahara, T.L., Wong, D.J., Werb, Z. and
Chang, H.Y. (2008) CSN5 isopeptidase activity links COP9 signalosome
activation to breast cancer progression. Cancer Res. 68, 506–515.
[41] Verma, U.N., Surabhi, R.M., Schmaltieg, A., Becerra, C. and Gaynor, R.B. (2003)
Small interfering RNAs directed against beta-catenin inhibit the in vitro and
in vivo growth of colon cancer cells. Clin. Cancer Res. 9, 1291–1300.
[42] Yang, J., Zhang, W., Evans, P.M., Chen, X., He, X. and Liu, C. (2006)
Adenomatous polyposis coli (APC) differentially regulates beta-catenin
phosphorylation and ubiquitination in colon cancer cells. J. Biol. Chem. 281.
11151-11151.
[43] Esteva, FJ. et al. (2003) Jun activation domain binding protein 1 expression is
associated with low p27(Kip1)levels in node-negative breast cancer. Clin.
Cancer Res. 9, 5652–5659.
[44] Hsu, M.C., Huang, C.C., Chang, H.C., Hu, T.H. and Hung, W.C. (2008)
Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by
peroxisome proliferator-activated receptor {gamma} ligands in vitro and
in vivo. Clin. Cancer Res. 14, 4045–4052.
[45] Goto, A. et al. (2004) Immunohistochemical study of Skp2 and Jab1, two key
molecules in the degradation of P27, in lung adenocarcinoma. Pathol. Int. 54,
675–681.
[46] Mori, M., Yoneda-Kato, N., Yoshida, A. and Kato, J.Y. (2008) Stable form of JAB1
enhances proliferation and maintenance of hematopoietic progenitors. J. Biol.
Chem. 283, 29011–29021.
[47] Huang, J., Yuan, H., Lu, C., Liu, X., Cao, X. and Wan, M. (2007) Jab1 mediates
protein degradation of the Rad9–Rad1–Hus1 checkpoint complex. J. Mol. Biol.
371, 514–527.
[48] Xiao, J.H. et al. (2003) Adenomatous polyposis coli (APC)-independent
regulation of beta-catenin degradation via a retinoid X receptor-mediated
pathway. J. Biol. Chem. 278, 29954–29962.
[49] Berg, J.P. et al. (2007) Inverse expression of Jun activation domain binding
protein 1 and cell cycle inhibitor p27Kip1: inﬂuence on proliferation in
hepatocellular carcinoma. Hum. Pathol. 38, 1621–1627.
[50] Kouvaraki, M.A. et al. (2006) Potential role of Jun activation domain-binding
protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma.
Cancer Res. 66, 8581–8589.
[51] Kleemann, R. et al. (2000) Intracellular action of the cytokine MIF to modulate
AP-1 activity and the cell cycle through Jab1. Nature 408, 211–216.
[52] Wilson, J.M. et al. (2005) Macrophage migration inhibitory factor promotes
intestinal tumorigenesis. Gastroenterology 129, 1485–1503.
[53] Schulz, R., Marchenko, N.D., Holembowski, L., Fingerle-Rowson, G., Pesic, M.,
Zender, L., Dobbelstein, M. and Moll, U.M. (2012) Inhibiting the HSP90
chaperone destabilizes macrophage migration inhibitory factor and thereby
inhibits breast tumor progression. J. Exp. Med. 209, 275–289.
[54] Fukumoto, A., Tomoda, K., Yoneda-Kato, N., Nakajima, Y. and Kato, J.Y. (2006)
Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines. FEBS
Lett. 580, 5836–5844.
[55] Davidson, G. and Niehrs, C. (2010) Emerging links between CDK cell cycle
regulators and Wnt signaling. Trends Cell Biol. 20, 453–460.
[56] Muncan, V. et al. (2006) Rapid loss of intestinal crypts upon conditional
deletion of the Wnt/Tcf-4 target gene c-Myc. Mol. Cell Biol. 26, 8418–8426.
[57] Juin, P., Hueber, A.O., Littlewood, T. and Evan, G. (1999) c-Myc-induced
sensitization to apoptosis is mediated through cytochrome c release. Genes
Dev. 13, 1367–1381.
[58] Klefstrom, J., Verschuren, E.W. and Evan, G. (2002) c-Myc augments the
apoptotic activity of cytosolic death receptor signaling proteins by engaging
the mitochondrial apoptotic pathway. J. Biol. Chem. 277, 43224–43232.
